Zanubrutinib

Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.

Cancer · Apr 2026

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.

Pharmacological research · Apr 2026

Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial.

Nature communications · Mar 2026

Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma.

Blood advances · Mar 2026

A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas.

Oncology and therapy · Mar 2026

Efficacy and safety of zanubrutinib combined with age-adapted bendamustine and rituximab followed by zanubrutinib maintenance therapy in elderly patients with mantle cell lymphoma: a retrospective analysis.

Leukemia & lymphoma · Mar 2026

Cutaneous Adverse Effects in Patients Treated with BTK Inhibitors.

Cancers · Jan 2026

BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders.

Biomolecules · Jan 2026

Zanubrutinib mitigates pulmonary fibrosis in aged mice by targeting the Wnt/β-catenin signaling pathway.

Biochemical pharmacology · Jan 2026

Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.

Leukemia & lymphoma · Dec 2025

Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.

Future oncology (London, England) · Oct 2025

Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors.

Blood research · Aug 2025

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update.

Pharmacological research · Jul 2025

Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma.

Journal of the National Comprehensive Cancer Network : JNCCN · Jun 2025

Indirect Comparisons of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with R/R MCL: An Extended Follow-up Analysis.

Advances in therapy · Jun 2025

From development to clinical success: the journey of established and next-generation BTK inhibitors.

Investigational new drugs · Apr 2025

Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · Mar 2025

Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib.

Journal of cellular and molecular medicine · Feb 2025

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.

Blood · Jan 2025

Establishment and Validation of a UPLC-MS/MS Method for Quantitative Determination of Zanubrutinib and Posaconazole in Rat Plasma: Application in Drug-Drug Interaction Studies.

Drug design, development and therapy · Jan 2025